Mr. Hani Zabaneh reports

ADAPTOGENICS APPOINTS ACCOMPLISHED PEPTIDE SCIENTIST DR. J. DAVID WARREN AS CHIEF EXECUTIVE OFFICER

Adaptogenics Health Corp. has appointed J. David Warren, PhD, as chief executive officer and as a director of the company, effective Oct. 1, 2026.

Dr. Warren brings more than two decades of experience in bioorganic chemistry, medicinal chemistry, peptide science and translational drug discovery. He is an adjunct associate professor of research in biochemistry and biophysics at Weill Cornell Medicine and formerly served as director of the Milstein chemistry core facility.

Dr. Warren has advanced multiple compounds into preclinical development, holds 17 issued United States and international patents, and has authored or coauthored more than 53 peer-reviewed publications and book chapters.

His published work includes foundational mechanistic research on SS 31, now known as elamipretide, a mitochondria targeted peptide that binds cardiolipin and supports mitochondrial bioenergetics. Elamipretide was subsequently developed as Forzinity and received accelerated approval from the United States Food and Drug Administration in September, 2025, as the first approved treatment for Barth syndrome.

Dr. Warren received his PhD from Colorado State University, where he was awarded a graduate fellowship from Boehringer Ingelheim. He completed postdoctoral research with Dr. Samuel J. Danishefsky at Memorial Sloan Kettering Cancer Center as an NIH supported fellow. He has also held senior scientific and executive positions at Lavior Pharma and Canary Oncoceutics.

"David changes the trajectory of this company," said Gurinder Sandhu, a director of Adaptogenics. "He brings a rare combination of peptide chemistry, medicinal chemistry and practical drug development experience. He understands how to move from a molecule and its mechanism to defensible intellectual property, credible evidence and a disciplined development plan."

"Adaptogenics has an opportunity to build valuable therapeutic programs by combining careful asset selection with rigorous scientific execution," said Dr. Warren. "I look forward to working with the team to build a focused pipeline supported by strong science, clear development pathways and meaningful intellectual property."

Under Dr. Warren's leadership, Adaptogenics intends to evaluate, acquire, design, and advance proprietary peptide and small molecule therapeutic candidates. Initial areas of evaluation include metabolic function, muscle strength and function during weight loss, mitochondrial biology, and the resolution of inflammation.

The company also announces the appointment of Gurinder Sandhu as executive vice-president, corporate development. Mr. Sandhu will continue serving as a director and will lead asset sourcing, strategic partnerships, institutional engagement, financing, and transaction execution.

In connection with Dr. Warren's appointment, Anthony Franco will step down as chief executive officer and as a director of the company effective Oct. 1, 2026. The board sincerely thanks Mr. Franco for his leadership through the company's strategic review, corporate transition and recent financing, which helped position Adaptogenics for its next phase.

Adoption of new omnibus equity incentive plan and issuance of stock options

In addition, the company's board of directors has adopted a new omnibus equity incentive plan to replace the company's existing 10-per-cent rolling stock option plan. The equity incentive plan provides for the grant of stock options, restricted share units, performance share units and deferred share units to eligible directors, employees and consultants. The maximum number of common shares issuable under the equity incentive plan is 20 per cent of the company's issued and outstanding common shares from time to time. The equity incentive plan remains subject to ratification by the company's shareholders at the company's next annual general meeting and acceptance by the Canadian Securities Exchange.

The company also announces that it has granted an aggregate of 800,000 stock options under the equity incentive plan to certain directors, officers and consultants of the company. Each option is exercisable to acquire one common share of the company at a price of 10 cents per share for a period of three years from the date of grant. The options vest as to 25 per cent on the date of grant and 25 per cent on each of the dates that are 12, 18 and 24 months following the date of grant. Vesting of the options is conditional upon receipt of all required approvals, including acceptance by the Canadian Securities Exchange and shareholder ratification of the equity incentive plan at the company's next annual general meeting. No option may be exercised unless and until all required approvals have been obtained.

About Adaptogenics Health Corp.

Adaptogenics Health is a Canadian based nutraceutical company that has focused on the formulation and distribution of functional mushroom products and nutritional supplement alternatives. The company is committed to its mission of improving and empowering human health and well-being.

We seek Safe Harbor.